Yarrow Bioscience, Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 74/100
What the filing says
Yarrow Bioscience entered into an underwriting agreement on September 10, 2026 to issue 5,769,231 firm shares at $24.44 per share, plus an option for underwriters to purchase up to 865,384 additional shares at the same price. Lead underwriters are Jefferies LLC, TD Securities (USA) LLC, and Guggenheim Securities LLC. Gross proceeds are approximately $140.8M before underwriting discounts. Closing is scheduled for September 14, 2026.
Why this rating
Major capital raise (~4.4x company market cap) providing substantial runway, but dilutive to shareholders. Positive for cash; negative for ownership percentage.
Price action (we called it neutral)
before filing · preread $26.26 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.